Letter by David et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) Randomized Trial"

Comment

Jean Stephane David et al. Circulation. 2013.

. 2013 Mar 19;127(11):e504.

doi: 10.1161/CIRCULATIONAHA.112.133041.

No abstract available

Comment in

Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”.
Healey JS, Eikelboom J, Yang S, Themeles E, Connolly SJ, Yusuf S, Douketis J, Wallentin L, Oldgren J, Heidbuchel H, Avezum A, Reilly P, Ezekowitz M. Healey JS, et al. Circulation. 2013 Mar 19;127(11):e506. doi: 10.1161/circulationaha.112.154732. Circulation. 2013. PMID: 23646374 No abstract available.

Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M; RE-LY Investigators. Healey JS, et al. Circulation. 2012 Jul 17;126(3):343-8. doi: 10.1161/CIRCULATIONAHA.111.090464. Epub 2012 Jun 14. Circulation. 2012. PMID: 22700854 Clinical Trial.